Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
Boehringer Ingelheim
Moodys
Baxter

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ALVIMOPAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Alvimopan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00101998 ↗ Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication Completed GlaxoSmithKline Phase 2 2003-10-01 A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.
NCT00101998 ↗ Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication Completed Cubist Pharmaceuticals LLC Phase 2 2003-10-01 A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.
NCT00135577 ↗ Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects Completed GlaxoSmithKline Phase 2 2004-09-01 Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.
NCT00135577 ↗ Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects Completed Cubist Pharmaceuticals LLC Phase 2 2004-09-01 Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.
NCT00205842 ↗ Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Completed GlaxoSmithKline Phase 3 2004-06-01 Patients undergoing major abdominal surgery are at highest risk for developing Postoperative Ileus (POI), occurring in nearly all cases. Signs and symptoms of POI may include abdominal distention and bloating, persistent abdominal pain; nausea and/or vomiting; variable reduction of bowel sounds; delayed passage of or inability to pass flatus or stool; and inability to tolerate a solid diet. This study will test the ability of alvimopan 12 mg given 30 to 90 minutes before the scheduled start of surgery to hasten the recovery of GI function in patients having partial small or large bowel resections.
NCT00205842 ↗ Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Completed Cubist Pharmaceuticals LLC Phase 3 2004-06-01 Patients undergoing major abdominal surgery are at highest risk for developing Postoperative Ileus (POI), occurring in nearly all cases. Signs and symptoms of POI may include abdominal distention and bloating, persistent abdominal pain; nausea and/or vomiting; variable reduction of bowel sounds; delayed passage of or inability to pass flatus or stool; and inability to tolerate a solid diet. This study will test the ability of alvimopan 12 mg given 30 to 90 minutes before the scheduled start of surgery to hasten the recovery of GI function in patients having partial small or large bowel resections.
NCT00241722 ↗ Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed GlaxoSmithKline Phase 3 2005-08-01 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo. The primary objective of this Phase 3 long-term safety study is to compare alvimopan with placebo for safety and tolerability in the treatment of OBD. Participants will be required to attend 8 clinic visits over approximately 1 year.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alvimopan

Condition Name

Condition Name for Alvimopan
Intervention Trials
Ileus 10
Bowel Dysfunction 6
Constipation 6
Postoperative Ileus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alvimopan
Intervention Trials
Ileus 14
Intestinal Diseases 10
Constipation 7
Gastrointestinal Diseases 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alvimopan

Trials by Country

Trials by Country for Alvimopan
Location Trials
United States 170
Canada 30
United Kingdom 16
Australia 14
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alvimopan
Location Trials
North Carolina 7
Pennsylvania 7
Ohio 7
California 7
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alvimopan

Clinical Trial Phase

Clinical Trial Phase for Alvimopan
Clinical Trial Phase Trials
Phase 4 6
Phase 3 12
Phase 2 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alvimopan
Clinical Trial Phase Trials
Completed 21
Recruiting 4
Terminated 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alvimopan

Sponsor Name

Sponsor Name for Alvimopan
Sponsor Trials
Cubist Pharmaceuticals LLC 15
GlaxoSmithKline 11
Merck Sharp & Dohme Corp. 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alvimopan
Sponsor Trials
Industry 32
Other 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Express Scripts
Boehringer Ingelheim
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.